|
|
|
|
LEADER |
00000cam a2200000Ma 4500 |
001 |
SCIDIR_ocn646754471 |
003 |
OCoLC |
005 |
20231117033214.0 |
006 |
m o d |
007 |
cr cn||||||||| |
008 |
750720s1992 nyua ob 001 0 eng d |
010 |
|
|
|z 52013360
|
040 |
|
|
|a E7B
|b eng
|e pn
|c E7B
|d OCLCQ
|d UBY
|d OCLCQ
|d OPELS
|d OCLCQ
|d OCLCF
|d N$T
|d IDEBK
|d YDXCP
|d OCLCQ
|d DEBSZ
|d LEAUB
|d VLY
|d INARC
|d OCLCO
|d OCLCQ
|
019 |
|
|
|a 261335525
|a 505089875
|a 906925460
|a 1162012721
|a 1397462837
|
020 |
|
|
|a 0120066602
|q (electronic bk.)
|
020 |
|
|
|a 9780120066605
|q (electronic bk.)
|
020 |
|
|
|a 9780080562421
|q (electronic bk.)
|
020 |
|
|
|a 0080562426
|q (electronic bk.)
|
020 |
|
|
|a 1281409251
|
020 |
|
|
|a 9781281409256
|
020 |
|
|
|a 9786611409258
|
020 |
|
|
|a 6611409254
|
035 |
|
|
|a (OCoLC)646754471
|z (OCoLC)261335525
|z (OCoLC)505089875
|z (OCoLC)906925460
|z (OCoLC)1162012721
|z (OCoLC)1397462837
|
050 |
|
4 |
|a RC267
|b .A4560 1992eb
|
072 |
|
7 |
|a MED
|x 062000
|2 bisacsh
|
072 |
|
7 |
|a HEA
|x 039030
|2 bisacsh
|
082 |
0 |
4 |
|a 616.9940072
|2 22
|
096 |
|
|
|a QZ 206
|f ADV
|
245 |
0 |
0 |
|a Advances in cancer research.
|n Volume 60 /
|c edited by George Vande Woude.
|
260 |
|
|
|a New York :
|b Academic Press,
|c 1992.
|
300 |
|
|
|a 1 online resource (312 pages) :
|b illustrations.
|
336 |
|
|
|a text
|b txt
|2 rdacontent
|
337 |
|
|
|a computer
|b c
|2 rdamedia
|
338 |
|
|
|a online resource
|b cr
|2 rdacarrier
|
490 |
0 |
|
|a Advances in cancer research ;
|v v. 60
|
504 |
|
|
|a Includes bibliographical references and index.
|
588 |
0 |
|
|a Print version record.
|
505 |
0 |
|
|a Front Cover; Advances in Cancer Research, Volume 60; Copyright Page; Contents; Contributors; Chapter 1. Structural and Functional Diversity in the FGF Receptor Multigene Family; I. Introduction; II. The FGF Family of Polypeptide Mitogens; III. Early Binding and Cross-Linking Studies of the FGF Receptor; IV. Nomenclature of the FGF Receptor Genes; V. Purification, cDNA Cloning, and Characterization of FGFR 1; VI. Characterization of EFGR 2, FGFR 3, and FGFR 4; VII. Multiple Forms of FGFR 1 and FGFR 2 Are Generated by Alternative Splicing; VIII. Multiple Forms of FGFR 1
|
505 |
8 |
|
|a IX. Multiple Forms of FGFR 2X. FGFR 3 and FGFR 4; XI. Ligand Binding Specificities of the Cloned FGF Receptors; XII. Alternative Splicing in the Third Ig Domain Is Important for Determining Ligand Binding Specificities; XIII. Analogous Splice Variants from Different FGF Receptor Genes Encode Receptor Forms with Different Ligand Binding Specificities; XIV. Regulation of FGF Receptor Expression; XV. Cell- and Tissue-Specific Alternative Splicing of FGF Receptor mRNAs; XVI. Differential, Tissue-Specific Expression of the Different ' FGF Receptor Genes; XVII. The Drosophila FGF Receptor
|
505 |
8 |
|
|a XVIII. FGF Receptor-Mediated Signal TransductionXIX. Concluding Remarks; References; Chapter 2. Protein Tyrosine Kinase Growth Factor Receptors and Their Ligands in Development, Differentiation, and Cancer; I. Introduction; II. Structure of Receptor Protein Tyrosine Kinases; III. RTKs in Development; IV. RTKs and Tumorigenesis; V. Genetics and Cancer; Reference; Chapter 3. The Molecular and Genetic Characterization of Human Soft Tissue Tumors; I. Introduction; II. Tumor Etiology; III. Genetic Susceptibility to Soft Tissue Tumors; IV. Detection of ras Gene Activation
|
505 |
8 |
|
|a V. Chromosomal AbnormalitiesVI. Tumor Suppressor Genes; VII. Gene Amplification; VIII. Predictors of Tumor Behavior; IX. Molecular Cloning of Translocation Breakpoints; X. Future Developments; Reference; Note Added in Proof; Chapter 4. Genomic instability and Tumor Progression: Mechanistic Considerations; I. Introduction; II. Genomic Stability and Instability: Background and Implications; III. Mechanisms of Genomic Stability and Instability; IV. Quantitative Considerations; V. Summary and Perspectives; References; Chapter 5. Function and Regulation of the Human Multidrug Resistance Gene
|
505 |
8 |
|
|a I. The Multidrug Transporter as a Cause of Multidrug ResistanceII. Regulation of Expression of mdr Genes; III. Summary and Conclusions; Reference; Chapter 6. Relationship between MYC Oncogene Activation and MHC Class I Expression; I. Introduction; II. MHC Class I Expression and Cancer; III. Modulation of MHC Class I Expression by Oncogences; IV. Molecular Mechanism of MHC Class I Regulation by Oncogenes; V. Biological Consequences of MHC Class I Downmodulation by Oncogenes; VI. Concluding Remarks; References; Chapter 7. Immunosuppressive Factors in Human Cancer; I. Introduction
|
520 |
|
|
|a ADVANCES IN CANCER RESEARCH, VOLUME 60.
|
546 |
|
|
|a English.
|
650 |
|
0 |
|a Cancer
|x Research.
|
650 |
|
0 |
|a Oncology, Experimental.
|
650 |
|
2 |
|a Neoplasms, Experimental
|0 (DNLM)D009374
|
650 |
|
6 |
|a Cancer
|x Recherche.
|0 (CaQQLa)201-0004697
|
650 |
|
6 |
|a Canc�erologie exp�erimentale.
|0 (CaQQLa)201-0049886
|
650 |
|
7 |
|a MEDICAL
|x Oncology.
|2 bisacsh
|
650 |
|
7 |
|a HEALTH & FITNESS
|x Diseases
|x Cancer.
|2 bisacsh
|
650 |
|
7 |
|a Cancer
|x Research.
|2 fast
|0 (OCoLC)fst00845497
|
650 |
|
7 |
|a Oncology, Experimental.
|2 fast
|0 (OCoLC)fst01045747
|
700 |
1 |
|
|a Vande Woude, George F.
|
776 |
0 |
8 |
|i Print version:
|t Advances in cancer research. Volume 60.
|d New York : Academic Press, 1992
|w (DLC) 52013360
|
856 |
4 |
0 |
|u https://sciencedirect.uam.elogim.com/science/book/9780120066605
|z Texto completo
|